

Franck Carbonnel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4683801/publications.pdf>

Version: 2024-02-01

62
papers

7,323
citations

201575

27
h-index

128225

60
g-index

63
all docs

63
docs citations

63
times ranked

10285
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , 2015, 350, 1079-1084.	6.0	2,539
2	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 769-784.	0.6	876
3	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1909-1915.	6.3	517
4	Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1679.	3.8	424
5	Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 337-346.e10.	0.6	411
6	Smoking cessation and the course of Crohn's disease: An intervention study. <i>Gastroenterology</i> , 2001, 120, 1093-1099.	0.6	384
7	Animal Protein Intake and Risk of Inflammatory Bowel Disease: The E3N Prospective Study. <i>American Journal of Gastroenterology</i> , 2010, 105, 2195-2201.	0.2	343
8	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018, 67, 2056-2067.	6.1	179
9	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. <i>Gut</i> , 2014, 63, 1416-1423.	6.1	122
10	Diet and risk of inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2012, 44, 185-194.	0.4	114
11	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 380-388.e4.	0.6	114
12	Heterogeneity of Colorectal Cancer Risk Factors by Anatomical Subsite in 10 European Countries: A Multinational Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1323-1331.e6.	2.4	99
13	The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 948-957.	1.9	84
14	Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. <i>Gut</i> , 2016, 65, 1664-1669.	6.1	81
15	Fibre intake and the development of inflammatory bowel disease: A European prospective multi-centre cohort study (EPIC-IBD). <i>Journal of Crohn's and Colitis</i> , 2018, 12, 129-136.	0.6	79
16	Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study. <i>Annals of Internal Medicine</i> , 2019, 170, 99.	2.0	76
17	Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study. <i>Journal of Hepatology</i> , 2019, 70, 885-892.	1.8	58
18	Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1289-1297.	1.9	57

#	ARTICLE	IF	CITATIONS
19	Interobserver Variation Study of the Rutgeerts Score to Assess Endoscopic Recurrence after Surgery for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1001-1005.	0.6	50
20	Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1393-1403.e1.	2.4	47
21	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 106-114.	1.3	41
22	Prediagnostic Serum Vitamin D Levels and the Risk of Crohn's Disease and Ulcerative Colitis in European Populations: A Nested Case-Control Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 633-640.	0.9	38
23	Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1239-1247.	0.6	38
24	Systematic review with meta-analysis: mortality in acute severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 8-33.	1.9	38
25	Isotretinoin and Risk of Inflammatory Bowel Disease: A French Nationwide Study. <i>American Journal of Gastroenterology</i> , 2014, 109, 563-569.	0.2	37
26	Efficacy and safety of extracorporeal shock wave lithotripsy for chronic pancreatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1380-1385.	0.6	30
27	Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1480-1490.	1.9	30
28	Patient, Procedure, and Endoscopist Risk Factors for Perforation, Bleeding, and Splenic Injury After Colonoscopies. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 719-727.e13.	2.4	29
29	Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 160-166.	1.9	29
30	Meat Intake Is Associated with a Higher Risk of Ulcerative Colitis in a Large European Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1187-1196.	0.6	27
31	A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1602-1610.e1.	2.4	26
32	Preoperative oral polymeric diet enriched with transforming growth factor-beta 2 (Modulen) could decrease postoperative morbidity after surgery for complicated ileocolonic Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 5-10.	0.6	25
33	Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?. <i>Seminars in Immunopathology</i> , 2017, 39, 327-331.	2.8	22
34	The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 269-277.	1.9	21
35	Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 302-311.	1.9	21
36	Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 380-388.	1.9	21

#	ARTICLE	IF	CITATIONS
37	Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1096-1104.	1.9	19
38	Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011-2013). <i>Digestive and Liver Disease</i> , 2016, 48, 620-625.	0.4	16
39	Drug use for gastrointestinal symptoms during pregnancy: A French nationwide study 2010-2018. <i>PLoS ONE</i> , 2021, 16, e0245854.	1.1	16
40	Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1269-1281.e9.	2.4	14
41	The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab. <i>Digestive and Liver Disease</i> , 2020, 52, 1148-1155.	0.4	13
42	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1180-1188.e4.	2.4	12
43	Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 218-225.	0.9	11
44	Diet and Risk of Cholecystectomy: A Prospective Study Based on the French E3N Cohort. <i>American Journal of Gastroenterology</i> , 2017, 112, 1448-1456.	0.2	11
45	Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. <i>Rheumatology</i> , 2020, 59, 3275-3283.	0.9	10
46	Methotrexate in IBD: The Return of the Prodigal Son. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 303-304.	0.6	8
47	Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1454-1462.	0.6	8
48	Somatostatin analogues for refractory diarrhoea in familial amyloid polyneuropathy. <i>PLoS ONE</i> , 2018, 13, e0201869.	1.1	4
49	Incidence of and Risk Factors for Systemic Adverse Events After Screening or Primary Diagnostic Colonoscopy: A Nationwide Cohort Study. <i>American Journal of Gastroenterology</i> , 2020, 115, 537-547.	0.2	4
50	Which Environmental Factors Cause IBD Relapses?. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1129-1131.	1.1	3
51	Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study. <i>Digestive and Liver Disease</i> , 2020, 52, 1323-1330.	0.4	3
52	Monitoring established Crohn's disease with pan-intestinal video capsule endoscopy in Europe: clinician consultation using the nominal group technique. <i>Current Medical Research and Opinion</i> , 2021, 37, 1547-1554.	0.9	3
53	Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101607.	0.7	3
54	Incidence, Phenotype, and Mortality of Inflammatory Bowel Disease - Twenty Years After. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1159-1160.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Towards more efficient assessment of ulcerative colitis drugs. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 8-9.	3.7	2
56	Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon. <i>EXCLI Journal</i> , 2021, 20, 819-827.	0.5	2
57	Response to Dai et al.. <i>American Journal of Gastroenterology</i> , 2014, 109, 1494-1495.	0.2	1
58	Reply. <i>Gastroenterology</i> , 2016, 151, 212-213.	0.6	1
59	Letter: choosing between ustekinumab and vedolizumab in anti- TNF refractory Crohn's disease—the devil is in the detail. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 563-564.	1.9	1
60	Editorial: subcutaneous $\text{CTA}\beta\text{P13}$ in Crohn's disease and ulcerative colitis—small change, big consequences. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 251-252.	1.9	1
61	Networks meet ulcerative colitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 730-731.	3.7	0
62	Letter: how can we reduce mortality in elderly patients with acute severe ulcerative colitis? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1445-1446.	1.9	0